carnitine has been researched along with Chronic Disease in 68 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study is to investigate the effectiveness of L-carnitine treatment in patients with dodementia stage chronic cerebral ischemia." | 9.17 | [L-carnitine treatment patients with chronic cerebral ischemia]. ( Fedin, AI; Fedotova, AV; Mironova, OP, 2013) |
| "To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines." | 9.14 | Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. ( Genova, C; Luigi Almasio, P; Milio, G; Novo, G; Novo, S; Pinto, A, 2009) |
| "In our study, myocardial-free carnitine levels were decreased while plasma-free carnitine levels were normal in patient with chronic rheumatic heart disease." | 9.08 | Carnitine levels in patients with chronic rheumatic heart disease. ( Andaç, H; Ceyran, H; Coşkun, A; Ergin, A; Narin, F; Narin, N; Ustdal, M, 1997) |
| "Bicycle ergometer exercise tests were used to study two groups of 10 subjects suffering from type A chronic respiratory insufficiency before and after a 4-week course of L-carnitine or placebo." | 9.06 | Effects of L-carnitine on physical performance in chronic respiratory insufficiency. ( Dal Negro, R; De Conti, F; Pomari, C; Turco, P, 1988) |
| "Propionyl-L-carnitine (PLC) is a naturally occurring compound that has been considered for the treatment of congestive heart failure (CHF)." | 8.79 | The propionyl-L-carnitine hypothesis: an alternative approach to treating heart failure. ( De Giuli, F; Ferrari, R, 1997) |
| "The effect of haemodialysis on peripheral blood lymphocyte levels of total carnitine (TC), free carnitine (FC) and acylcarnitine (AC), and on the ratio of AC to FC, is investigated in 20 healthy subjects (13 men and seven women) and 27 patients (10 men and 17 women) with chronic pyelonephritis." | 7.70 | Effect of haemodialysis on peripheral lymphocyte carnitine levels in patients with chronic pyelonephritis. ( Alhomida, AS, 1999) |
| "The effect of acetate and bicarbonate haemodialysis (HD) on the concentrations of erythrocyte, whole-blood and plasma total carnitine (TC), free carnitine (FC), short- (SC) and long-chain acylcarnitine (LC) and acylcarnitine (AC) as well as the ratio of AC to FC was investigated in 30 healthy subjects (15 men and 15 women) and 27 patients (10 men and 17 women) with chronic pyelonephritis (CPN) undergoing chronic HD." | 7.70 | Influence of acetate and bicarbonate dialysate on blood short- and long-chain acyl carnitine in adult pyelonephritis patients. ( Alhomida, AS, 1999) |
| "To study the tissue carnitine level in patients with chronic heart failure, we obtained biopsy specimens of the left ventricular papillary muscle from 8 patients with mitral valve disease undergoing valve replacement surgery." | 7.68 | Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure. ( Kobayashi, A; Masumura, Y; Yamazaki, N, 1990) |
| "To evaluate the therapeutic efficacy of l-carnitine in heart failure, the myocardial carnitine levels and the therapeutic efficacy of l-carnitine were studied in cardiomyopathic BIO 14." | 7.68 | L-carnitine treatment for congestive heart failure--experimental and clinical study. ( Kobayashi, A; Masumura, Y; Yamazaki, N, 1992) |
| "The therapeutic effect of L-carnitine on arrhythmias during hemodialysis was evaluated in 17 patients with chronic renal disease undergoing intermittent hemodialysis." | 7.66 | Effects of L-carnitine on arrhythmias during hemodialysis. ( Narita, M; Suzuki, Y; Yamazaki, N, 1982) |
| " Group 1, composed of 25 patients, was treated with leucocytic IFN-alpha at a dosage of 3 million IU thrice a week; group 2 (25 patients) was treated with the same protocol as group 1, but was also administered carnitine 2 g per os daily." | 6.71 | L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. ( Luca, S; Malaguarnera, M; Neri, S; Pennisi, G; Pistone, G; Saraceno, B, 2003) |
| "L-carnitine plays a critical role in fatty acid transport into the mitochondria and may thus influence inflammation and myocardial function." | 5.39 | Disturbed carnitine regulation in chronic heart failure--increased plasma levels of palmitoyl-carnitine are associated with poor prognosis. ( Askevold, ET; Aukrust, P; Berge, RK; Bjørndal, B; Dahl, CP; Gullestad, L; Nymoen, SH; Svardal, A; Ueland, T; Øie, E, 2013) |
| "Carnitine is a conditionally essential metabolite that plays a critical role in cell physiology." | 5.34 | Advances in carnitine in chronic uremia. ( Barazzoni, R; Biolo, G; Guarnieri, G; Massolino, B; Vinci, P, 2007) |
| "The purpose of this study is to investigate the effectiveness of L-carnitine treatment in patients with dodementia stage chronic cerebral ischemia." | 5.17 | [L-carnitine treatment patients with chronic cerebral ischemia]. ( Fedin, AI; Fedotova, AV; Mironova, OP, 2013) |
| "To evaluate the therapeutic effects of L-propionyl-carnitine (LPC) in patients with critical limb ischemia (CLI), as defined by the TASC guidelines." | 5.14 | Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1. ( Genova, C; Luigi Almasio, P; Milio, G; Novo, G; Novo, S; Pinto, A, 2009) |
| "In our study, myocardial-free carnitine levels were decreased while plasma-free carnitine levels were normal in patient with chronic rheumatic heart disease." | 5.08 | Carnitine levels in patients with chronic rheumatic heart disease. ( Andaç, H; Ceyran, H; Coşkun, A; Ergin, A; Narin, F; Narin, N; Ustdal, M, 1997) |
| "Bicycle ergometer exercise tests were used to study two groups of 10 subjects suffering from type A chronic respiratory insufficiency before and after a 4-week course of L-carnitine or placebo." | 5.06 | Effects of L-carnitine on physical performance in chronic respiratory insufficiency. ( Dal Negro, R; De Conti, F; Pomari, C; Turco, P, 1988) |
| " We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis." | 4.91 | Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015) |
| "Propionyl-L-carnitine (PLC) is a naturally occurring compound that has been considered for the treatment of congestive heart failure (CHF)." | 4.79 | The propionyl-L-carnitine hypothesis: an alternative approach to treating heart failure. ( De Giuli, F; Ferrari, R, 1997) |
| "A panel of gut-related biomarkers including metabolites of the choline/carnitine- pathway (acetyl-L-carnitine, betaine, choline, γ-butyrobetaine, L-carnitine and trimethylamine-N-oxide [TMAO]) and the gut peptide, Trefoil factor-3 (TFF-3), were investigated in 1,783 patients with worsening HF enrolled in the systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) cohort and associations with HF severity and outcomes, and use in risk stratification were assessed." | 4.12 | Surrogate markers of gut dysfunction are related to heart failure severity and outcome-from the BIOSTAT-CHF consortium. ( Anker, SD; Cleland, JG; Israr, MZ; Lang, CC; Metra, M; Ng, LL; Salzano, A; Samani, NJ; Suzuki, T; van Veldhuisen, DJ; Voors, AA; Zannad, F; Zhan, H, 2022) |
| "To evaluate the effects of L-carnitine oral supplementation on anemia and cardiac function in patients on maintenance hemodialysis (HD), we studied 55 adult chronic HD patients at our center during the period from January 2006 to June 2006 and divided them into two groups; a group of 20 patients who received 1500 mg/day oral L-carnitine and a control group of 35 patients." | 3.76 | The role of oral L-carnitine therapy in chronic hemodialysis patients. ( Sabry, AA, 2010) |
| " Chronic hypothyroidism was associated with substantial depletion in skeletal muscle free carnitine." | 3.75 | Longitudinal study of the effects of chronic hypothyroidism on skeletal muscle in dogs. ( Duncan, RB; Inzana, KD; Panciera, DL; Rossmeisl, JH; Shelton, GD, 2009) |
| "The effects of chronic hypoxia on cardiac membrane fatty acids and on lipid peroxidation were examined, as well as the effect of l-carnitine (LCAR), which suppresses lipid peroxidation, on this process." | 3.74 | Change in the membranous lipid composition accelerates lipid peroxidation in young rat hearts subjected to 2 weeks of hypoxia followed by hyperoxia. ( Hamaoka, K; Itoi, T; Nakanishi, H; Oka, T; Taguchi, R; Terada, N, 2008) |
| "The effect of acetate and bicarbonate haemodialysis (HD) on the concentrations of erythrocyte, whole-blood and plasma total carnitine (TC), free carnitine (FC), short- (SC) and long-chain acylcarnitine (LC) and acylcarnitine (AC) as well as the ratio of AC to FC was investigated in 30 healthy subjects (15 men and 15 women) and 27 patients (10 men and 17 women) with chronic pyelonephritis (CPN) undergoing chronic HD." | 3.70 | Influence of acetate and bicarbonate dialysate on blood short- and long-chain acyl carnitine in adult pyelonephritis patients. ( Alhomida, AS, 1999) |
| "The effect of haemodialysis on peripheral blood lymphocyte levels of total carnitine (TC), free carnitine (FC) and acylcarnitine (AC), and on the ratio of AC to FC, is investigated in 20 healthy subjects (13 men and seven women) and 27 patients (10 men and 17 women) with chronic pyelonephritis." | 3.70 | Effect of haemodialysis on peripheral lymphocyte carnitine levels in patients with chronic pyelonephritis. ( Alhomida, AS, 1999) |
| "To evaluate the therapeutic efficacy of l-carnitine in heart failure, the myocardial carnitine levels and the therapeutic efficacy of l-carnitine were studied in cardiomyopathic BIO 14." | 3.68 | L-carnitine treatment for congestive heart failure--experimental and clinical study. ( Kobayashi, A; Masumura, Y; Yamazaki, N, 1992) |
| "To study the tissue carnitine level in patients with chronic heart failure, we obtained biopsy specimens of the left ventricular papillary muscle from 8 patients with mitral valve disease undergoing valve replacement surgery." | 3.68 | Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure. ( Kobayashi, A; Masumura, Y; Yamazaki, N, 1990) |
| "The therapeutic effect of L-carnitine on arrhythmias during hemodialysis was evaluated in 17 patients with chronic renal disease undergoing intermittent hemodialysis." | 3.66 | Effects of L-carnitine on arrhythmias during hemodialysis. ( Narita, M; Suzuki, Y; Yamazaki, N, 1982) |
| " Group 1, composed of 25 patients, was treated with leucocytic IFN-alpha at a dosage of 3 million IU thrice a week; group 2 (25 patients) was treated with the same protocol as group 1, but was also administered carnitine 2 g per os daily." | 2.71 | L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. ( Luca, S; Malaguarnera, M; Neri, S; Pennisi, G; Pistone, G; Saraceno, B, 2003) |
| "Many patients with ischemic heart disease continue to experience anginal symptoms despite revascularization and treatment with antianginal medications." | 2.43 | Metabolic modulators for chronic cardiac ischemia. ( Arora, R; Parang, P; Singh, B, 2005) |
| "Carnitine plays an important role in the utilization of fatty acids in the myocardium." | 1.42 | Impact of sleep-disordered breathing on myocardial damage and metabolism in patients with chronic heart failure. ( Kunii, H; Miyata, M; Nakazato, K; Owada, T; Saitoh, S; Sato, T; Sugimoto, K; Suzuki, H; Suzuki, S; Takeishi, Y; Yamaki, T; Yamauchi, H; Yoshihisa, A, 2015) |
| "Dietary patterns related to type 2 diabetes-relevant metabolites included high intake of red meat and low intake of whole-grain bread, tea, coffee, cake and cookies, canned fruits and fish." | 1.39 | Variation of serum metabolites related to habitual diet: a targeted metabolomic approach in EPIC-Potsdam. ( Adamski, J; Boeing, H; Drogan, D; Floegel, A; Pischon, T; Prehn, C; Schulze, MB; von Ruesten, A, 2013) |
| "L-carnitine plays a critical role in fatty acid transport into the mitochondria and may thus influence inflammation and myocardial function." | 1.39 | Disturbed carnitine regulation in chronic heart failure--increased plasma levels of palmitoyl-carnitine are associated with poor prognosis. ( Askevold, ET; Aukrust, P; Berge, RK; Bjørndal, B; Dahl, CP; Gullestad, L; Nymoen, SH; Svardal, A; Ueland, T; Øie, E, 2013) |
| "Carnitine is a conditionally essential metabolite that plays a critical role in cell physiology." | 1.34 | Advances in carnitine in chronic uremia. ( Barazzoni, R; Biolo, G; Guarnieri, G; Massolino, B; Vinci, P, 2007) |
| "Carnitine is an essential cofactor in the transfer of long-chain fatty acids across the inner mitochondrial membrane for oxidation." | 1.31 | Plasma and liver carnitine status of children with chronic liver disease and cirrhosis. ( Aydogdu, S; Huseyinov, A; Selimoglu, MA; Yagci, RV, 2001) |
| "Carnitine metabolism was studied in 79 patients with chronic liver disease, including 22 patients with noncirrhotic liver disease and 57 patients with different types of cirrhosis (22 patients with hepatitis B- or C-associated cirrhosis, 15 patients with alcohol-induced cirrhosis, 15 patients with primary biliary cirrhosis [PBC], and 5 patients with cryptogenic cirrhosis), and compared with 28 control subjects." | 1.30 | Carnitine metabolism in patients with chronic liver disease. ( Krähenbühl, S; Reichen, J, 1997) |
| "In patients with bacterial infections the granulocyte carnitine concentrations (126." | 1.29 | The variation of carnitine content in human blood cells during disease--a study in bacterial infection and inflammatory bowel disease. ( Böhles, H; Demirkol, M; Sewell, AC, 1994) |
| "Myo-inositol concentration was decreased in liver, heart and kidney but not in brain, pancreas and skeletal muscle." | 1.28 | Effect of short- and long-term diabetes on carnitine and myo-inositol in rats. ( Baker, H; DeAngelis, B; Frank, O; Jyothirmayi, GN; Reddi, AS, 1991) |
| ") at a dosage of 1." | 1.28 | Cerebral blood flow in patients with chronic cerebrovascular disease: effect of acetyl L-carnitine. ( Cicerano, U; De Chiara, S; Gallotta, G; Mancini, M; Postiglione, A; Salvatore, M; Soricelli, A, 1990) |
| "L-Carnitine treatment of the diabetic rats increased myocardial free-carnitine levels, which were comparable with those of control rats." | 1.27 | Effect of L-carnitine treatment on lipid metabolism and cardiac performance in chronically diabetic rats. ( McNeill, JH; Rodrigues, B; Xiang, H, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (17.65) | 18.7374 |
| 1990's | 20 (29.41) | 18.2507 |
| 2000's | 13 (19.12) | 29.6817 |
| 2010's | 18 (26.47) | 24.3611 |
| 2020's | 5 (7.35) | 2.80 |
| Authors | Studies |
|---|---|
| Dean, DA | 1 |
| Gautham, G | 1 |
| Siqueira-Neto, JL | 1 |
| McKerrow, JH | 1 |
| Dorrestein, PC | 1 |
| McCall, LI | 1 |
| Israr, MZ | 1 |
| Zhan, H | 1 |
| Salzano, A | 1 |
| Voors, AA | 1 |
| Cleland, JG | 1 |
| Anker, SD | 1 |
| Metra, M | 1 |
| van Veldhuisen, DJ | 1 |
| Lang, CC | 1 |
| Zannad, F | 1 |
| Samani, NJ | 1 |
| Ng, LL | 1 |
| Suzuki, T | 1 |
| Crocetto, F | 1 |
| Boccellino, M | 1 |
| Barone, B | 1 |
| Di Zazzo, E | 1 |
| Sciarra, A | 1 |
| Galasso, G | 1 |
| Settembre, G | 1 |
| Quagliuolo, L | 1 |
| Imbimbo, C | 1 |
| Boffo, S | 1 |
| Angelillo, IF | 1 |
| Di Domenico, M | 1 |
| Wei, H | 1 |
| Zhao, M | 1 |
| Huang, M | 1 |
| Li, C | 1 |
| Gao, J | 1 |
| Yu, T | 1 |
| Zhang, Q | 1 |
| Shen, X | 1 |
| Ji, L | 1 |
| Ni, L | 1 |
| Zhao, C | 1 |
| Wang, Z | 1 |
| Dong, E | 1 |
| Zheng, L | 1 |
| Wang, DW | 1 |
| Skoromets, AA | 1 |
| Kotov, SV | 1 |
| Voronkov, PB | 1 |
| Popova, VV | 1 |
| Zubkova, TG | 1 |
| Kiselev, AV | 1 |
| Statsenko, ME | 1 |
| Turkina, SV | 1 |
| Ohba, K | 1 |
| Sinha, RA | 1 |
| Singh, BK | 1 |
| Iannucci, LF | 1 |
| Zhou, J | 1 |
| Kovalik, JP | 1 |
| Liao, XH | 1 |
| Refetoff, S | 1 |
| Sng, JCG | 1 |
| Leow, MK | 1 |
| Yen, PM | 1 |
| Xie, X | 1 |
| Guo, A | 1 |
| Wu, T | 1 |
| Hu, Q | 1 |
| Huang, L | 1 |
| Yao, C | 1 |
| Zhao, B | 1 |
| Zhang, W | 1 |
| Chi, B | 1 |
| Lu, P | 1 |
| Zhao, Z | 1 |
| Fu, Z | 1 |
| Marcinkiewicz-Siemion, M | 1 |
| Ciborowski, M | 1 |
| Ptaszynska-Kopczynska, K | 1 |
| Szpakowicz, A | 1 |
| Lisowska, A | 1 |
| Jasiewicz, M | 1 |
| Waszkiewicz, E | 1 |
| Kretowski, A | 1 |
| Musial, WJ | 1 |
| Kaminski, KA | 1 |
| Moreira da Silva Guimarães, S | 1 |
| de Souza Cruz, WM | 1 |
| de Souza Weigert, G | 1 |
| Scalco, FB | 1 |
| Colafranceschi, AS | 1 |
| Ribeiro, MG | 1 |
| Boaventura, GT | 1 |
| Fedotova, AV | 1 |
| Mironova, OP | 1 |
| Fedin, AI | 1 |
| Floegel, A | 1 |
| von Ruesten, A | 1 |
| Drogan, D | 1 |
| Schulze, MB | 1 |
| Prehn, C | 1 |
| Adamski, J | 1 |
| Pischon, T | 1 |
| Boeing, H | 1 |
| Bjørndal, B | 2 |
| Berge, C | 1 |
| Ramsvik, MS | 1 |
| Svardal, A | 2 |
| Bohov, P | 1 |
| Skorve, J | 1 |
| Berge, RK | 2 |
| Miyata, M | 1 |
| Yoshihisa, A | 1 |
| Yamauchi, H | 1 |
| Owada, T | 1 |
| Sato, T | 1 |
| Suzuki, S | 1 |
| Sugimoto, K | 1 |
| Yamaki, T | 1 |
| Kunii, H | 1 |
| Nakazato, K | 1 |
| Suzuki, H | 1 |
| Saitoh, S | 1 |
| Takeishi, Y | 1 |
| Bonafé, L | 1 |
| Berger, MM | 1 |
| Que, YA | 1 |
| Mechanick, JI | 1 |
| Ryckman, KK | 1 |
| Smith, CJ | 1 |
| Jelliffe-Pawlowski, LL | 1 |
| Momany, AM | 1 |
| Berberich, SL | 1 |
| Murray, JC | 1 |
| Akaishi, T | 1 |
| Nakashima, I | 1 |
| Misu, T | 1 |
| Fujihara, K | 1 |
| Aoki, M | 1 |
| Mücke, M | 1 |
| Cuhls, H | 1 |
| Peuckmann-Post, V | 1 |
| Minton, O | 1 |
| Stone, P | 1 |
| Radbruch, L | 1 |
| Ganai, AA | 1 |
| Ganaie, IA | 1 |
| Verma, N | 1 |
| Farooqi, H | 1 |
| Couce, ML | 1 |
| Aldamiz-Echevarría, L | 1 |
| Bueno, MA | 1 |
| Barros, P | 1 |
| Belanger-Quintana, A | 1 |
| Blasco, J | 1 |
| García-Silva, MT | 1 |
| Márquez-Armenteros, AM | 1 |
| Vitoria, I | 1 |
| Vives, I | 1 |
| Navarrete, R | 1 |
| Fernández-Marmiesse, A | 1 |
| Pérez, B | 1 |
| Pérez-Cerdá, C | 1 |
| Oka, T | 1 |
| Itoi, T | 1 |
| Terada, N | 1 |
| Nakanishi, H | 1 |
| Taguchi, R | 1 |
| Hamaoka, K | 1 |
| Milio, G | 1 |
| Novo, G | 1 |
| Genova, C | 1 |
| Luigi Almasio, P | 1 |
| Novo, S | 1 |
| Pinto, A | 1 |
| Rossmeisl, JH | 1 |
| Duncan, RB | 1 |
| Inzana, KD | 1 |
| Panciera, DL | 1 |
| Shelton, GD | 1 |
| Sabry, AA | 1 |
| Hoofnagle, JH | 1 |
| Sarkar, S | 1 |
| Zhou, L | 1 |
| Wang, Q | 1 |
| Yin, P | 1 |
| Xing, W | 1 |
| Wu, Z | 1 |
| Chen, S | 1 |
| Lu, X | 1 |
| Zhang, Y | 1 |
| Lin, X | 1 |
| Xu, G | 1 |
| Ueland, T | 1 |
| Øie, E | 1 |
| Askevold, ET | 1 |
| Nymoen, SH | 1 |
| Dahl, CP | 1 |
| Gullestad, L | 1 |
| Aukrust, P | 1 |
| Neri, S | 1 |
| Pistone, G | 1 |
| Saraceno, B | 1 |
| Pennisi, G | 2 |
| Luca, S | 2 |
| Malaguarnera, M | 1 |
| Maeda, H | 1 |
| Hirakata, H | 1 |
| Parang, P | 1 |
| Singh, B | 1 |
| Arora, R | 1 |
| Lin, XH | 1 |
| Jiao, LL | 1 |
| Xu, GB | 1 |
| Tian, GS | 1 |
| Guarnieri, G | 1 |
| Biolo, G | 1 |
| Vinci, P | 1 |
| Massolino, B | 1 |
| Barazzoni, R | 1 |
| Bonomini, M | 1 |
| Sirolli, V | 1 |
| Dottori, S | 1 |
| Amoroso, L | 1 |
| Di Liberato, L | 1 |
| Arduini, A | 1 |
| Suzuki, Y | 2 |
| Masumura, Y | 3 |
| Kobayashi, A | 3 |
| Yamazaki, N | 4 |
| Harada, Y | 1 |
| Osawa, M | 1 |
| Narita, M | 1 |
| Kudoh, Y | 1 |
| Shoji, T | 1 |
| Oimatsu, H | 1 |
| Yoshida, S | 1 |
| Kikuchi, K | 1 |
| Iimura, O | 1 |
| Giorcelli, G | 1 |
| Vacha, G | 1 |
| Icardi, GP | 1 |
| Demirkol, M | 1 |
| Sewell, AC | 1 |
| Böhles, H | 1 |
| Michalak, A | 1 |
| Qureshi, IA | 1 |
| Krähenbühl, S | 2 |
| Reichen, J | 1 |
| Serjeant, BE | 1 |
| Harris, J | 1 |
| Thomas, P | 1 |
| Serjeant, GR | 1 |
| Ferrari, R | 1 |
| De Giuli, F | 1 |
| Narin, F | 1 |
| Narin, N | 1 |
| Andaç, H | 1 |
| Ergin, A | 1 |
| Coşkun, A | 1 |
| Ustdal, M | 1 |
| Ceyran, H | 1 |
| Gleim, GG | 1 |
| Glace, B | 1 |
| Kalinowski, M | 1 |
| Popławski, A | 1 |
| Mazerska, M | 1 |
| Daniluk, A | 1 |
| Alhomida, AS | 2 |
| Iyer, RN | 1 |
| Khan, AA | 1 |
| Gupta, A | 1 |
| Vajifdar, BU | 1 |
| Lokhandwala, YY | 1 |
| Terranova, R | 1 |
| Selimoglu, MA | 1 |
| Aydogdu, S | 1 |
| Yagci, RV | 1 |
| Huseyinov, A | 1 |
| Signorelli, SS | 1 |
| Malaponte, G | 1 |
| Di Pino, L | 1 |
| Digrandi, D | 1 |
| Mazzarino, MC | 1 |
| Williams, ES | 1 |
| Luft, FC | 1 |
| Murakami, K | 1 |
| Sugimoto, T | 1 |
| Nishida, N | 1 |
| Kobayashi, Y | 1 |
| Kuhara, T | 1 |
| Matsumoto, I | 1 |
| Fernandez, C | 1 |
| Proto, C | 1 |
| Reddi, AS | 1 |
| Jyothirmayi, GN | 1 |
| DeAngelis, B | 1 |
| Frank, O | 1 |
| Baker, H | 1 |
| Melegh, B | 1 |
| Kerner, J | 1 |
| Acsádi, G | 1 |
| Lakatos, J | 1 |
| Sándor, A | 1 |
| Postiglione, A | 1 |
| Cicerano, U | 1 |
| Soricelli, A | 1 |
| De Chiara, S | 1 |
| Gallotta, G | 1 |
| Salvatore, M | 1 |
| Mancini, M | 1 |
| Deshchekina, MF | 1 |
| Demin, VF | 1 |
| Kliuchnikov, SO | 1 |
| Khamaganova, IV | 1 |
| Rodrigues, B | 1 |
| Xiang, H | 1 |
| McNeill, JH | 1 |
| Byrne, E | 1 |
| Trounce, I | 1 |
| Dal Negro, R | 1 |
| Turco, P | 1 |
| Pomari, C | 1 |
| De Conti, F | 1 |
| Medvedev, DI | 1 |
| Babichenko, II | 1 |
| Eremina, IZ | 1 |
| Kravtsova, AI | 1 |
| Kondrup, J | 1 |
| Grunnet, N | 1 |
| Huth, W | 1 |
| Dierich, C | 1 |
| von Oeynhausen, V | 1 |
| Seubert, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924] | 42 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | |||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for carnitine and Chronic Disease
| Article | Year |
|---|---|
The Crosstalk between Prostate Cancer and Microbiota Inflammation: Nutraceutical Products Are Useful to Balance This Interplay?
Topics: Acetylcysteine; Carnitine; Chronic Disease; Dietary Supplements; Disease Progression; Fatty Acids, U | 2020 |
Carnitine deficiency in chronic critical illness.
Topics: Cardiomyopathies; Carnitine; Chronic Disease; Critical Illness; Fatty Acids; Humans; Hyperammonemia; | 2014 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea | 2015 |
[Hyporesponsiveness to recombinant human erythropoietin therapy in anemic patients on hemodialysis].
Topics: Aluminum; Anemia; Angiotensin-Converting Enzyme Inhibitors; Carnitine; Chronic Disease; Drug Resista | 2004 |
Metabolic modulators for chronic cardiac ischemia.
Topics: Acetanilides; Animals; Carnitine; Chronic Disease; Drug Evaluation, Preclinical; Enzyme Inhibitors; | 2005 |
Carnitine metabolism in chronic liver disease.
Topics: Animals; Carnitine; Chronic Disease; Fatty Liver; Fatty Liver, Alcoholic; Hepatitis, Viral, Human; H | 1996 |
The propionyl-L-carnitine hypothesis: an alternative approach to treating heart failure.
Topics: Animals; Cardiotonic Agents; Carnitine; Chronic Disease; Disease Models, Animal; Heart; Heart Failur | 1997 |
[L-carnitine in the treatment of chronic myocardial ischemia. An analysis of 3 multicenter studies and a bibliographic review].
Topics: Angina Pectoris; Carnitine; Chronic Disease; Coronary Disease; Drug Evaluation; Germany; Humans; Ita | 1992 |
12 trials available for carnitine and Chronic Disease
| Article | Year |
|---|---|
Topics: Acetylcarnitine; Aged; Cardiovascular Diseases; Carnitine; Cerebrovascular Disorders; Chronic Diseas | 2021 |
[L-carnitine treatment patients with chronic cerebral ischemia].
Topics: Adult; Aged; Brain Ischemia; Carnitine; Chronic Disease; Dose-Response Relationship, Drug; Female; F | 2013 |
Pharmacological treatment of patients with chronic critical limb ischemia: L-propionyl-carnitine enhances the short-term effects of PGE-1.
Topics: Aged; Alprostadil; Cardiotonic Agents; Carnitine; Chronic Disease; Double-Blind Method; Drug Synergi | 2009 |
L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C.
Topics: Adult; Carnitine; Case-Control Studies; Chronic Disease; Drug Interactions; Fatigue; Female; Hepatit | 2003 |
L-carnitine inhibits a subset of platelet activation responses in chronic uraemia.
Topics: Aged; Blood Platelets; Carnitine; Caspases; Chronic Disease; Female; Humans; Kidney Failure, Chronic | 2007 |
Propionyl-L-carnitine in chronic leg ulcers of homozygous sickle cell disease: a pilot study.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Carnitine; Chronic Disease; Double-Blind Method; Female; Hom | 1997 |
Carnitine levels in patients with chronic rheumatic heart disease.
Topics: Adult; Carnitine; Chronic Disease; Female; Humans; Male; Middle Aged; Rheumatic Heart Disease | 1997 |
Study on propionyl-L-carnitine in chronic heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Carnitine; Chronic Disease; Diuretics; | 1999 |
L-carnitine moderately improves the exercise tolerance in chronic stable angina.
Topics: Adult; Analysis of Variance; Angina Pectoris; Carnitine; Chronic Disease; Drug Administration Schedu | 2000 |
Effects of ischaemic stress on leukocyte activation processes in patients with chronic peripheral occlusive arterial disease: role of L-propionyl carnitine administration.
Topics: Aged; Arteriosclerosis; Cardiotonic Agents; Carnitine; Cell Adhesion Molecules; Chronic Disease; E-S | 2001 |
[L-carnitine in the treatment of chronic myocardial ischemia. An analysis of 3 multicenter studies and a bibliographic review].
Topics: Angina Pectoris; Carnitine; Chronic Disease; Coronary Disease; Drug Evaluation; Germany; Humans; Ita | 1992 |
Effects of L-carnitine on physical performance in chronic respiratory insufficiency.
Topics: Bicarbonates; Blood Gas Analysis; Carbon Dioxide; Carnitine; Chronic Disease; Exercise Test; Humans; | 1988 |
49 other studies available for carnitine and Chronic Disease
| Article | Year |
|---|---|
Spatial metabolomics identifies localized chemical changes in heart tissue during chronic cardiac Chagas Disease.
Topics: Animals; Carnitine; Chagas Cardiomyopathy; Chronic Disease; Heart; Humans; Male; Metabolomics; Mice; | 2021 |
Surrogate markers of gut dysfunction are related to heart failure severity and outcome-from the BIOSTAT-CHF consortium.
Topics: Acetylcarnitine; Biomarkers; Carnitine; Choline; Chronic Disease; Heart Failure; Humans | 2022 |
FMO3-TMAO axis modulates the clinical outcome in chronic heart-failure patients with reduced ejection fraction: evidence from an Asian population.
Topics: Carnitine; Choline; Chronic Disease; Heart Failure; Humans; Methylamines; Oxygenases; Prospective St | 2022 |
Changes in Hepatic TRβ Protein Expression, Lipogenic Gene Expression, and Long-Chain Acylcarnitine Levels During Chronic Hyperthyroidism and Triiodothyronine Withdrawal in a Mouse Model.
Topics: Adipogenesis; Animals; Body Weight; Carnitine; Chronic Disease; Disease Models, Animal; Gene Express | 2017 |
Preventive effect of L-carnitine on the disorder of lipid metabolism and circadian clock of mice subjected to chronic jet-lag.
Topics: Animals; Carnitine; Chronic Disease; Circadian Clocks; Circadian Rhythm; Jet Lag Syndrome; Lipid Met | 2017 |
LC-MS-based serum fingerprinting reveals significant dysregulation of phospholipids in chronic heart failure.
Topics: Aged; Carnitine; Cholesterol; Chromatography, Liquid; Chronic Disease; Cohort Studies; Fatty Acids; | 2018 |
Decompensated Chronic Heart Failure Reduces Plasma L-carnitine.
Topics: Aged; Carnitine; Chronic Disease; Cross-Sectional Studies; Energy Metabolism; Fatty Acids; Female; H | 2018 |
Variation of serum metabolites related to habitual diet: a targeted metabolomic approach in EPIC-Potsdam.
Topics: Adult; Amino Acids; Carnitine; Chronic Disease; Cross-Sectional Studies; Diabetes Mellitus, Type 2; | 2013 |
A fish protein hydrolysate alters fatty acid composition in liver and adipose tissue and increases plasma carnitine levels in a mouse model of chronic inflammation.
Topics: Adipose Tissue; Animals; Carnitine; Caseins; Chronic Disease; Diet, High-Fat; Fatty Acids, Omega-3; | 2013 |
Impact of sleep-disordered breathing on myocardial damage and metabolism in patients with chronic heart failure.
Topics: Adult; Aged; Biomarkers; Carnitine; Chronic Disease; Female; Heart Failure; Humans; Male; Middle Age | 2015 |
Metabolic heritability at birth: implications for chronic disease research.
Topics: Acyl-CoA Dehydrogenase; Acyl-CoA Dehydrogenases; Adult; Carnitine; Chronic Disease; Female; Humans; | 2014 |
Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica.
Topics: Adult; Aged; Carnitine; Chronic Disease; Comorbidity; Depression; Fatigue; Female; Gait Disorders, N | 2015 |
Regression of fibrosis/cirrhosis by Glycine propionyl-l-carnitine treatment in d-Galactosamine induced chronic liver damage.
Topics: Actins; Animals; Body Weight; Carnitine; Chronic Disease; Collagen Type I; Galactosamine; Gene Expre | 2016 |
Genotype and phenotype characterization in a Spanish cohort with isovaleric acidemia.
Topics: Acute Disease; Amino Acid Metabolism, Inborn Errors; Asymptomatic Diseases; Carnitine; Child; Child, | 2017 |
Change in the membranous lipid composition accelerates lipid peroxidation in young rat hearts subjected to 2 weeks of hypoxia followed by hyperoxia.
Topics: Acetylcarnitine; Age Factors; Animals; Antioxidants; Carnitine; Catalase; Cell Membrane; Chronic Dis | 2008 |
Longitudinal study of the effects of chronic hypothyroidism on skeletal muscle in dogs.
Topics: Animals; Carnitine; Chronic Disease; Dog Diseases; Dogs; Female; Hypothyroidism; Muscle, Skeletal; M | 2009 |
The role of oral L-carnitine therapy in chronic hemodialysis patients.
Topics: Administration, Oral; Adult; Anemia; Carnitine; Chronic Disease; Dietary Supplements; Echocardiograp | 2010 |
Fatigue and serum carnitine levels in chronic liver disease.
Topics: Carnitine; Chronic Disease; Fatigue; Humans; Liver Diseases; Severity of Illness Index | 2011 |
Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases.
Topics: Carcinoma, Hepatocellular; Carnitine; Chromatography, Liquid; Chronic Disease; Fatty Acids; Humans; | 2012 |
Disturbed carnitine regulation in chronic heart failure--increased plasma levels of palmitoyl-carnitine are associated with poor prognosis.
Topics: Adult; Aged; Biomarkers; Carnitine; Chronic Disease; Disease Progression; Female; Heart Failure; Hum | 2013 |
[Significance of serum carnitine in patients with liver diseases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carnitine; Chronic Disease; Female; Hepatitis, Viral, Hu | 2006 |
Advances in carnitine in chronic uremia.
Topics: Carnitine; Chronic Disease; Energy Metabolism; Homeostasis; Humans; Kidney Failure, Chronic; Renal D | 2007 |
Myocardial carnitine deficiency in chronic heart failure.
Topics: Animals; Carnitine; Chronic Disease; Guinea Pigs; Heart Failure; Humans; Myocardium | 1982 |
Effects of L-carnitine on arrhythmias during hemodialysis.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Carnitine; Chronic Disease; Fatty A | 1982 |
The role of L-carnitine in the pathogenesis of cardiomegaly in patients with chronic hemodialysis.
Topics: Adolescent; Adult; Aged; Cardiomegaly; Carnitine; Cholesterol; Cholesterol, HDL; Chronic Disease; Fe | 1983 |
Drug treatment of hypertriglyceridaemia in chronic uraemic patients: preliminary report on D,L-carnitine and thiadenol.
Topics: Carnitine; Chronic Disease; Clofibrate; Fatty Alcohols; Humans; Hyperlipoproteinemias; Lipid Metabol | 1980 |
The variation of carnitine content in human blood cells during disease--a study in bacterial infection and inflammatory bowel disease.
Topics: Acute Disease; Adolescent; Adult; Bacterial Infections; Carnitine; Child; Chronic Disease; Crohn Dis | 1994 |
Tissue acylcarnitine and acyl-coenzyme A profiles in chronically hyperammonemic mice treated with sodium benzoate and supplementary L-carnitine.
Topics: Acetylcarnitine; Acyl Coenzyme A; Ammonia; Animals; Benzoates; Benzoic Acid; Carnitine; Chronic Dise | 1995 |
Carnitine metabolism in patients with chronic liver disease.
Topics: Adult; Aged; Bilirubin; Carnitine; Chronic Disease; Humans; Liver Cirrhosis; Liver Diseases; Middle | 1997 |
Carnitine as an ergogenic aid in health and disease.
Topics: Carnitine; Chronic Disease; Dietary Supplements; Exercise; Humans; Oxygen Consumption | 1998 |
[Effects of L-carnitine on erythropoiesis and blood platelet aggregation in patients with chronic renal failure treated with hemodialysis].
Topics: Adult; Carnitine; Chronic Disease; Erythropoiesis; Erythropoietin; Female; Humans; Male; Middle Aged | 1999 |
Influence of acetate and bicarbonate dialysate on blood short- and long-chain acyl carnitine in adult pyelonephritis patients.
Topics: Acetates; Adult; Bicarbonates; Carnitine; Chronic Disease; Erythrocytes; Female; Humans; Male; Pyelo | 1999 |
Effect of haemodialysis on peripheral lymphocyte carnitine levels in patients with chronic pyelonephritis.
Topics: Carnitine; Chronic Disease; Female; Humans; Lymphocytes; Male; Pyelonephritis; Renal Dialysis | 1999 |
[Treatment of chronic arterial occlusive disease of the lower limbs with propionyl-1-carnitine in elderly patients].
Topics: Aged; Arterial Occlusive Diseases; Cardiotonic Agents; Carnitine; Chronic Disease; Female; Humans; L | 2001 |
Plasma and liver carnitine status of children with chronic liver disease and cirrhosis.
Topics: Adolescent; Adult; Carnitine; Child; Child, Preschool; Chronic Disease; Female; Hepatolenticular Deg | 2001 |
The effect of chronic uremia on fatty acid metabolism in the heart.
Topics: Animals; Blood Pressure; Body Weight; Carnitine; Chronic Disease; Creatinine; Fatty Acids; Hematocri | 1978 |
Abnormal metabolism of carnitine and valproate in a case of acute encephalopathy during chronic valproate therapy.
Topics: Brain Diseases; Carnitine; Cerebral Palsy; Child; Chronic Disease; Female; Gas Chromatography-Mass S | 1992 |
L-carnitine treatment for congestive heart failure--experimental and clinical study.
Topics: Adult; Angina Pectoris; Animals; Cardiomyopathies; Carnitine; Chronic Disease; Cricetinae; Drug Eval | 1992 |
Effect of short- and long-term diabetes on carnitine and myo-inositol in rats.
Topics: Acute Disease; Animals; Blood Glucose; Body Weight; Carnitine; Chronic Disease; Diabetes Mellitus, E | 1991 |
Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure.
Topics: Adult; Aged; Animals; Autopsy; Biopsy; Carnitine; Chronic Disease; Dogs; Female; Heart Failure; Hear | 1990 |
L-carnitine replacement therapy in chronic valproate treatment.
Topics: Adolescent; Carnitine; Child; Chronic Disease; Epilepsy; Female; Humans; Ketone Bodies; Lipid Metabo | 1990 |
Cerebral blood flow in patients with chronic cerebrovascular disease: effect of acetyl L-carnitine.
Topics: Acetylcarnitine; Aged; Arteriosclerosis; Carnitine; Cerebrovascular Circulation; Cerebrovascular Dis | 1990 |
[Effects of antioxidants on content of bioelements in the blood of newborn infants after chronic intrauterine hypoxia].
Topics: Antioxidants; Carnitine; Chronic Disease; Copper; Fetal Hypoxia; Humans; Infant, Newborn; Iron; Sele | 1990 |
[Dipromonium in the treatment of scleroderma patients].
Topics: Adolescent; Adult; Aged; Carnitine; Chronic Disease; Dermatologic Agents; Drug Evaluation; Drug Ther | 1989 |
Effect of L-carnitine treatment on lipid metabolism and cardiac performance in chronically diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Carnitine; Cholesterol; Chronic Disease; Diabetes Mellitus, Exp | 1988 |
Chronic fatigue and myalgia syndrome: mitochondrial and glycolytic studies in skeletal muscle.
Topics: Adult; Aged; Aged, 80 and over; Asthenia; Carnitine; Chronic Disease; Electron Transport Complex IV; | 1987 |
[Ultrastructural characteristics of the neocortex during rehabilitation from the sequelae of long-term protein-energy deficiency].
Topics: Animals; Carnitine; Cerebral Cortex; Chronic Disease; Dietary Proteins; Mice; Mice, Inbred CBA; Micr | 1985 |
The effect of acute and prolonged ethanol treatment on the contents of coenzyme A, carnitine and their derivatives in rat liver.
Topics: Acetyl Coenzyme A; Acetylation; Acute Disease; Acylation; Acyltransferases; Alcoholic Intoxication; | 1973 |
On the mechanism of ketogenesis and its control. I. On a possible role of acetoacetyl-CoA thiolase in the control of ketone body production.
Topics: Acetates; Acetoacetates; Acetyltransferases; Acute Disease; Animals; Aspartic Acid; Carbon Radioisot | 1973 |